ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $173 | -47.7% | 15,500 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $331 | -80.9% | 15,500 | -63.9% | 0.00% | -66.7% |
| Q1 2023 | $1,734 | +160.8% | 42,900 | +200.0% | 0.00% | 0.0% |
| Q4 2022 | $665 | -99.9% | 14,300 | 0.0% | 0.00% | -25.0% |
| Q3 2022 | $741,000 | +5.3% | 14,300 | -4.0% | 0.00% | +33.3% |
| Q2 2022 | $704,000 | -29.8% | 14,900 | +5.7% | 0.00% | -25.0% |
| Q1 2022 | $1,003,000 | -4.8% | 14,100 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,054,000 | +78.6% | 14,100 | +35.6% | 0.00% | +100.0% |
| Q3 2021 | $590,000 | -10.6% | 10,400 | -30.7% | 0.00% | 0.0% |
| Q2 2021 | $660,000 | -1.5% | 15,000 | +10.3% | 0.00% | -33.3% |
| Q1 2021 | $670,000 | +17.1% | 13,600 | 0.0% | 0.00% | +50.0% |
| Q4 2020 | $572,000 | -8.0% | 13,600 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $622,000 | -8.8% | 13,600 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $682,000 | +6.2% | 13,600 | +8.8% | 0.00% | 0.0% |
| Q1 2020 | $642,000 | -16.8% | 12,500 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $772,000 | -45.5% | 12,500 | -47.0% | 0.00% | 0.0% |
| Q3 2019 | $1,416,000 | +52.6% | 23,600 | +114.5% | 0.00% | -25.0% |
| Q2 2019 | $928,000 | +991.8% | 11,000 | +1122.2% | 0.00% | – |
| Q1 2019 | $85,000 | +34.9% | 900 | 0.0% | 0.00% | – |
| Q4 2018 | $63,000 | -93.6% | 900 | -92.2% | 0.00% | -100.0% |
| Q3 2018 | $991,000 | -20.8% | 11,600 | +7.4% | 0.00% | -20.0% |
| Q2 2018 | $1,251,000 | +32.2% | 10,800 | -7.7% | 0.01% | +25.0% |
| Q1 2018 | $946,000 | -4.0% | 11,700 | -30.4% | 0.00% | 0.0% |
| Q4 2017 | $985,000 | +20.3% | 16,800 | -4.0% | 0.00% | 0.0% |
| Q3 2017 | $819,000 | +11.7% | 17,500 | -14.2% | 0.00% | +33.3% |
| Q2 2017 | $733,000 | +6.4% | 20,400 | -8.9% | 0.00% | 0.0% |
| Q1 2017 | $689,000 | -10.5% | 22,400 | -2.6% | 0.00% | 0.0% |
| Q4 2016 | $770,000 | +12.7% | 23,000 | -10.5% | 0.00% | 0.0% |
| Q3 2016 | $683,000 | +6.9% | 25,700 | -11.4% | 0.00% | 0.0% |
| Q2 2016 | $639,000 | -10.0% | 29,000 | +19.8% | 0.00% | 0.0% |
| Q1 2016 | $710,000 | -4.3% | 24,200 | +7.6% | 0.00% | 0.0% |
| Q4 2015 | $742,000 | +0.3% | 22,500 | +9.8% | 0.00% | -25.0% |
| Q3 2015 | $740,000 | -11.1% | 20,500 | +10.8% | 0.00% | 0.0% |
| Q2 2015 | $832,000 | +18.7% | 18,500 | -19.2% | 0.00% | +33.3% |
| Q1 2015 | $701,000 | -23.0% | 22,900 | +27.9% | 0.00% | -25.0% |
| Q4 2014 | $910,000 | -35.7% | 17,900 | -50.0% | 0.00% | +33.3% |
| Q3 2014 | $1,416,000 | +93.4% | 35,800 | +110.6% | 0.00% | 0.0% |
| Q2 2014 | $732,000 | +10.2% | 17,000 | +2.4% | 0.00% | 0.0% |
| Q1 2014 | $664,000 | +180.2% | 16,600 | +90.8% | 0.00% | +200.0% |
| Q4 2013 | $237,000 | +6.8% | 8,700 | -10.3% | 0.00% | 0.0% |
| Q3 2013 | $222,000 | +640.0% | 9,700 | +470.6% | 0.00% | – |
| Q2 2013 | $30,000 | – | 1,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |